Skip to main content
Erschienen in: Current Cardiovascular Risk Reports 6/2013

01.12.2013 | Elderly and Heart Disease (J Wei and G Azhar, Section Editors)

New Approaches to Treating Cardiac Cachexia in the Older Patient

verfasst von: Gohar Azhar, Jeanne Y. Wei

Erschienen in: Current Cardiovascular Risk Reports | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Congestive heart failure (CHF) is a leading cause of morbidity and mortality in the elderly, accounting for more hospitalizations than any other condition. Advanced stages of congestive heart failure can be associated with serious complications such as cardiac cachexia (defined here as unintentional weight loss of more than 6 % in 6 months). Cardiac cachexia and the associated progressive weight loss are sometimes overlooked by older patients, their families and care providers. A delay in the diagnosis can result in further loss of vital organ tissue, progressive weakness, fall-related injuries and even long-term care institutionalization and/or death. During the past several years, researchers have begun to broaden their understanding of this common, morbid and often fatal condition, and these findings will help to characterize the features that assist in its diagnosis, minimize its exacerbation, delay the progressive decline, and educate clinicians about the potential management options.
Literatur
2.
Zurück zum Zitat Forman DE, Wei JY. Congestive heart failure in the elderly. In: Sheehan MN, Wei JY, editors. Geriatric Medicine: A case-based manual. New York: Oxford University Press; 1997. p. 67–79. Forman DE, Wei JY. Congestive heart failure in the elderly. In: Sheehan MN, Wei JY, editors. Geriatric Medicine: A case-based manual. New York: Oxford University Press; 1997. p. 67–79.
3.
Zurück zum Zitat Samuel RS, Hausdorff J, Wei JY. Congestive heart failure with preserved systolic function: is it a woman’s disease? Women’s Health Issues. 1999;9:219–22.PubMedCrossRef Samuel RS, Hausdorff J, Wei JY. Congestive heart failure with preserved systolic function: is it a woman’s disease? Women’s Health Issues. 1999;9:219–22.PubMedCrossRef
4.
Zurück zum Zitat Kyne L, Hausdorff JM, Knight E, Dukas L, Azhar G, Wei JY. Neutrophilia and congestive heart failure following acute myocardial infarction. Am Heart J. 2000;139:94–100.PubMedCrossRef Kyne L, Hausdorff JM, Knight E, Dukas L, Azhar G, Wei JY. Neutrophilia and congestive heart failure following acute myocardial infarction. Am Heart J. 2000;139:94–100.PubMedCrossRef
5.
Zurück zum Zitat Azhar G, Wei JY. In: Lang F, editor. Mechanisms of heart failure. Encyclopedia of molecular mechanisms of disease. Heidelberg: Springer Verlag; 2009. p. 781–2. Azhar G, Wei JY. In: Lang F, editor. Mechanisms of heart failure. Encyclopedia of molecular mechanisms of disease. Heidelberg: Springer Verlag; 2009. p. 781–2.
6.
Zurück zum Zitat Genth-Zotz S, von Haehling S, Bolger AP, Kalra PR, Wensel R, Coats AJ, et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol. 2002;90(11):1226–30. PubMed PMID: 12450603.PubMedCrossRef Genth-Zotz S, von Haehling S, Bolger AP, Kalra PR, Wensel R, Coats AJ, et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol. 2002;90(11):1226–30. PubMed PMID: 12450603.PubMedCrossRef
7.
Zurück zum Zitat Melenovsky V, Kotrc M, Borlaug BA, Marek T, Kovar J, Malek I et al. Relationships between Right Ventricular Function, Body Composition and Prognosis in Advanced Heart Failure. J Am Coll Cardiol. 2013 Jul 20 [Epub]. Melenovsky V, Kotrc M, Borlaug BA, Marek T, Kovar J, Malek I et al. Relationships between Right Ventricular Function, Body Composition and Prognosis in Advanced Heart Failure. J Am Coll Cardiol. 2013 Jul 20 [Epub].
8.
Zurück zum Zitat Pureza V, Florea VG. Mechanisms for Cachexia in Heart Failure. Curr Heart Fail Rep. 2013 Aug 8 [Epub]. Pureza V, Florea VG. Mechanisms for Cachexia in Heart Failure. Curr Heart Fail Rep. 2013 Aug 8 [Epub].
9.
Zurück zum Zitat Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, et al. Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine. 2013;43(3):626–34.PubMedCrossRef Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, et al. Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine. 2013;43(3):626–34.PubMedCrossRef
10.
Zurück zum Zitat Callahan DM, Toth MJ. Skeletal muscle protein metabolism in human heart failure. Curr Opin Clin Nutr Metab Care. 2013;16(1):66–71.PubMedCrossRef Callahan DM, Toth MJ. Skeletal muscle protein metabolism in human heart failure. Curr Opin Clin Nutr Metab Care. 2013;16(1):66–71.PubMedCrossRef
11.
Zurück zum Zitat von Haehling S, Anker SD, Doehner W, Morley JE, Vellas B. Frailty and heart disease. Int J Cardiol. 2013 Aug 7[Epub]. von Haehling S, Anker SD, Doehner W, Morley JE, Vellas B. Frailty and heart disease. Int J Cardiol. 2013 Aug 7[Epub].
12.
Zurück zum Zitat •• Szabó T, Scherbakov N, Sandek A, Kung T, von Haehling S, Lainscak M et al. Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis. 2013 Jun 18 [Epub]. This study showed that a high adiponectin level was an independent prognostic indicator of cardiac cachexia severity and was significantly associated with morbidity and mortality. •• Szabó T, Scherbakov N, Sandek A, Kung T, von Haehling S, Lainscak M et al. Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis. 2013 Jun 18 [Epub]. This study showed that a high adiponectin level was an independent prognostic indicator of cardiac cachexia severity and was significantly associated with morbidity and mortality.
13.
Zurück zum Zitat Barbosa-Ferreira JM, Fernandes F, Dabarian A, Mady C. Leptin in heart failure. Expert Opin Med Diagn. 2013;7(1):113–7.PubMedCrossRef Barbosa-Ferreira JM, Fernandes F, Dabarian A, Mady C. Leptin in heart failure. Expert Opin Med Diagn. 2013;7(1):113–7.PubMedCrossRef
14.
Zurück zum Zitat • Zamboni M, Rossi A, Corzato F, Bambace C, Mazzali G, Fantin F. Sarcopenia, Cachexia and Congestive Heart Failure in the Elderly. Endocr Metab Immune Disord Drug Targets. 2013 Jan 15. This study describes the pathophysiological abnormalities in the muscle that distinguishes sarcopenia from cardiac cachexia. • Zamboni M, Rossi A, Corzato F, Bambace C, Mazzali G, Fantin F. Sarcopenia, Cachexia and Congestive Heart Failure in the Elderly. Endocr Metab Immune Disord Drug Targets. 2013 Jan 15. This study describes the pathophysiological abnormalities in the muscle that distinguishes sarcopenia from cardiac cachexia.
15.
Zurück zum Zitat Fülster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34(7):512–9.PubMedCrossRef Fülster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34(7):512–9.PubMedCrossRef
16.
Zurück zum Zitat Valentová M, von Haehling S, Doehner W, Murín J, Anker SD, Sandek A. Liver dysfunction and its nutritional implications in heart failure. Nutrition. 2013;29(2):370–8.PubMedCrossRef Valentová M, von Haehling S, Doehner W, Murín J, Anker SD, Sandek A. Liver dysfunction and its nutritional implications in heart failure. Nutrition. 2013;29(2):370–8.PubMedCrossRef
17.
Zurück zum Zitat Azhar G, Wei JY. Nutrition and cardiac cachexia. Curr Opin Clin Nutr Metab Care. 2006;9:18–23.PubMedCrossRef Azhar G, Wei JY. Nutrition and cardiac cachexia. Curr Opin Clin Nutr Metab Care. 2006;9:18–23.PubMedCrossRef
18.
Zurück zum Zitat • Bindels LB, Delzenne NM. Muscle wasting: The gut microbiota as a new therapeutic target? Int J Biochem Cell Biol. 2013 Jul 4 [Epub]. This review describes evidence for the role of gut microbiota in muscle wasting and the potential therapeutic options targeting the gut-muscle axis for prevention and treatment. • Bindels LB, Delzenne NM. Muscle wasting: The gut microbiota as a new therapeutic target? Int J Biochem Cell Biol. 2013 Jul 4 [Epub]. This review describes evidence for the role of gut microbiota in muscle wasting and the potential therapeutic options targeting the gut-muscle axis for prevention and treatment.
19.
Zurück zum Zitat Mondal AK, Das SK, Varma V, Nolen GT, McGehee RE, Elbein SC, et al. Effect of endoplasmic reticulum stress on inflammation and adiponectin regulation in human adipocytes. Metab Syndr Relat Disord. 2012;10(4):297–306.PubMedCrossRef Mondal AK, Das SK, Varma V, Nolen GT, McGehee RE, Elbein SC, et al. Effect of endoplasmic reticulum stress on inflammation and adiponectin regulation in human adipocytes. Metab Syndr Relat Disord. 2012;10(4):297–306.PubMedCrossRef
20.
Zurück zum Zitat Perkel D, Naghi J, Agarwal M, Morrissey RP, Phan A, Willix Jr RD, et al. Potential effects of IGF-1 and GH on patients with chronic heart failure. J Cardiovasc Pharmacol Ther. 2012;17(1):72–8. doi:10.1177/1074248411402078. Epub 2011 Mar 31. Review. PubMed PMID: 21454724.PubMedCrossRef Perkel D, Naghi J, Agarwal M, Morrissey RP, Phan A, Willix Jr RD, et al. Potential effects of IGF-1 and GH on patients with chronic heart failure. J Cardiovasc Pharmacol Ther. 2012;17(1):72–8. doi:10.​1177/​1074248411402078​. Epub 2011 Mar 31. Review. PubMed PMID: 21454724.PubMedCrossRef
21.
Zurück zum Zitat Yoshida T, Tabony AM, Galvez S, Mitch WE, Higashi Y, Sukhanov S, et al. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol. 2013. doi:10.1016/j.biocel. PubMed PMID: 23769949.PubMed Yoshida T, Tabony AM, Galvez S, Mitch WE, Higashi Y, Sukhanov S, et al. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol. 2013. doi:10.​1016/​j.​biocel. PubMed PMID: 23769949.PubMed
22.
Zurück zum Zitat Szabó T, Postrach E, Mähler A, Kung T, Turhan G, von Haehling S et al. Increased catabolic activity in adipose tissue of patients with chronic heart failure. Eur J Heart Fail. 2013 May 21 [Epub]. Szabó T, Postrach E, Mähler A, Kung T, Turhan G, von Haehling S et al. Increased catabolic activity in adipose tissue of patients with chronic heart failure. Eur J Heart Fail. 2013 May 21 [Epub].
23.
Zurück zum Zitat •• Yoshida T, Tabony AM, Galvez S, Mitch WE, Higashi Y, Sukhanov S, et al. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol. 2013. doi:10.1016/j.biocel.2013.05.035. [Epub ahead of print] PubMed PMID: 23769949. This study enumerates RAS or Ang II signaling blockade as a promising target for the treatment of muscle atrophy or cachexia. •• Yoshida T, Tabony AM, Galvez S, Mitch WE, Higashi Y, Sukhanov S, et al. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol. 2013. doi:10.​1016/​j.​biocel.​2013.​05.​035. [Epub ahead of print] PubMed PMID: 23769949. This study enumerates RAS or Ang II signaling blockade as a promising target for the treatment of muscle atrophy or cachexia.
24.
Zurück zum Zitat Adams V, Linke A, Wisloff U, Döring C, Erbs S, Kränkel N, et al. Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc Res. 2007;73(1):120–9. PMID: 17145048.PubMedCrossRef Adams V, Linke A, Wisloff U, Döring C, Erbs S, Kränkel N, et al. Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc Res. 2007;73(1):120–9. PMID: 17145048.PubMedCrossRef
26.
Zurück zum Zitat •• Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachex Sarcopenia Muscle. 2010;1(1):35–42. This study showed that high calorie-protein supplements can significantly improve quality of life and reduce serum levels of tumor necrosis factor-α in cardiac cachexia. •• Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachex Sarcopenia Muscle. 2010;1(1):35–42. This study showed that high calorie-protein supplements can significantly improve quality of life and reduce serum levels of tumor necrosis factor-α in cardiac cachexia.
27.
Zurück zum Zitat Johnson C, Williams R, Wei JY, Ranganathan G. Regulation of serum response factor and adiponectin by PPARγ agonist docosahexaenoic acid. J Lipids. 2011;2011:670479.PubMed Johnson C, Williams R, Wei JY, Ranganathan G. Regulation of serum response factor and adiponectin by PPARγ agonist docosahexaenoic acid. J Lipids. 2011;2011:670479.PubMed
28.
Zurück zum Zitat Steinman J, DeBoer MD. Treatment of cachexia: melanocortin and ghrelin interventions. Vitam Horm. 2013;92:197–242.PubMedCrossRef Steinman J, DeBoer MD. Treatment of cachexia: melanocortin and ghrelin interventions. Vitam Horm. 2013;92:197–242.PubMedCrossRef
29.
Zurück zum Zitat Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 2013;280(17):4294–314.PubMedCrossRef Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 2013;280(17):4294–314.PubMedCrossRef
30.
Zurück zum Zitat Wang Y, Pessin JE. Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care. 2013;16(3):243–50.PubMedCrossRef Wang Y, Pessin JE. Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care. 2013;16(3):243–50.PubMedCrossRef
31.
Zurück zum Zitat • Krim SR, Campbell P, Lavie CJ, Ventura H. Micronutrients in chronic heart failure. Curr Heart Fail Rep. 2013;10(1):46–53. Study highlights the importance of micronutrient deficiencies as potential contributing factors in development of cardiac cachexia. • Krim SR, Campbell P, Lavie CJ, Ventura H. Micronutrients in chronic heart failure. Curr Heart Fail Rep. 2013;10(1):46–53. Study highlights the importance of micronutrient deficiencies as potential contributing factors in development of cardiac cachexia.
Metadaten
Titel
New Approaches to Treating Cardiac Cachexia in the Older Patient
verfasst von
Gohar Azhar
Jeanne Y. Wei
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Cardiovascular Risk Reports / Ausgabe 6/2013
Print ISSN: 1932-9520
Elektronische ISSN: 1932-9563
DOI
https://doi.org/10.1007/s12170-013-0353-6

Weitere Artikel der Ausgabe 6/2013

Current Cardiovascular Risk Reports 6/2013 Zur Ausgabe

Smoking and Lifestyle (R Huxley, Section Editor)

Effectiveness of Electronic Aids for Smoking Cessation

Elderly and Heart Disease (J Wei and G Azhar, Section Editors)

Update on Heart Failure with Preserved Ejection Fraction

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.